These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 16680113)

  • 21. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 23. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 24. Post-market approval surveillance: a call for a more integrated and comprehensive approach.
    Mehran R; Leon MB; Feigal DA; Jefferys D; Simons M; Chronos N; Fogarty TJ; Kuntz RE; Baim DS; Kaplan AV
    Circulation; 2004 Jun; 109(25):3073-7. PubMed ID: 15226222
    [No Abstract]   [Full Text] [Related]  

  • 25. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
    Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
    Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
    [No Abstract]   [Full Text] [Related]  

  • 26. Reforms on drug safety.
    Nature; 2006 Sep; 443(7110):372. PubMed ID: 17006474
    [No Abstract]   [Full Text] [Related]  

  • 27. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prepare for the long haul of drug monitoring.
    Gliklich R
    Nat Med; 2010 Aug; 16(8):848. PubMed ID: 20689542
    [No Abstract]   [Full Text] [Related]  

  • 29. A dual track system to give more-rapid access to new drugs: applying a systems mindset to the US food and drug administration (FDA).
    Madden BJ
    Med Hypotheses; 2009 Feb; 72(2):116-20. PubMed ID: 19036524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 32. Report hits FDA to revamp safety oversight.
    Finkelstein JB
    J Natl Cancer Inst; 2006 Jul; 98(13):884-5. PubMed ID: 16818849
    [No Abstract]   [Full Text] [Related]  

  • 33. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 34. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

  • 35. Mandatory post marketing studies.
    Somberg J
    Am J Ther; 2007; 14(4):321. PubMed ID: 17667203
    [No Abstract]   [Full Text] [Related]  

  • 36. Post-marketing strategies for medicines.
    Breckenridge A
    Clin Pharmacol Ther; 2008 Jan; 83(1):24-5; discussion 25. PubMed ID: 18043682
    [No Abstract]   [Full Text] [Related]  

  • 37. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities.
    DiMartino LD; Curtis LH; Williams RL; Abernethy DR; Schulman KA
    Food Drug Law J; 2008; 63(4):891-900. PubMed ID: 19601387
    [No Abstract]   [Full Text] [Related]  

  • 38. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 39. Production of high-quality marketing applications: strategies for biotechnology companies working with contract research organizations.
    Hecker SJ; Preston C; Foote M
    Biotechnol Annu Rev; 2003; 9():269-77. PubMed ID: 14650931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric drug development in anesthesiology: an FDA perspective.
    Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
    Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.